We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Diet and Risk of Amyotrophic Lateral Sclerosis Is Lifestyle Important?

Michael Swash, MD1,2
[+] Author Affiliations
1Royal London Hospital, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, England
2Institute of Neuroscience, University of Lisbon, Lisbon, Portugal
JAMA Neurol. 2014;71(9):1085-1086. doi:10.1001/jamaneurol.2014.1894.
Text Size: A A A
Published online


Amyotrophic lateral sclerosis (ALS) is usually considered to begin when the first symptoms develop; an example is the onset of distal weakness and atrophy in an upper limb, often with fasciculation in a more widespread distribution.1 This definition of disease onset follows an understanding of the pattern of onset in other acquired neurological diseases and is rooted in the history of neurology. However, neurodegenerative disorders as a group seem characteristically to begin gradually and subclinically without a clearly defined moment of onset. Obvious examples are Alzheimer-type dementia, Huntington disease, Parkinson disease, and many peripheral neuropathies, whether genetic or acquired, such as diabetic neuropathy. Even monogenetic disorders such as Huntington disease or the Charcot-Marie-Tooth syndromes exhibit gradual and indefinable onset patterns. Because the onset of ALS, as distinct from its diagnostic clinical features, cannot be defined, the question arises whether there is a long preclinical phase of accumulation of pathology or toxic metabolites in the cytosol. This concept is presently undefined and virtually unstudied, at least in human ALS,2 although it may be possible to address it in transgenic rodent models. In sporadic ALS, there is accumulation of cytosolic TDP43 (transactive response DNA binding protein 43 kDa), a protein derived from RNA metabolism; this protein is also found in other recognized forms of mutation-related ALS, although not in superoxide dismutase–related ALS. The variation in age at onset and clinical phenotype of ALS suggests a possible analogy with the inverse relationship between birth weight and the risk of cerebrovascular disease and type 2 diabetes mellitus, which is sometimes termed the metabolic syndrome X.3

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles